Welcome to SIGA Technologies

At SIGA, we specialize in developing therapeutic solutions for some of the most lethal pathogens – smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Our objective is to discover, develop, and commercialize drugs to prevent and treat these high-priority threats.

Our Lead Product Candidate, Tecovirimat

Our lead product candidate, tecovirimat (aka ST-246^®) is a drug under development for the treatment of smallpox – one of the deadliest diseases that mankind has ever faced and a formidable bioterrorism and biowarfare threat.

SIGA has entered into a contract, in excess of $400 million, with the Biomedical Advanced Research and Development Authority (BARDA) for the delivery of 2 million courses of tecovirimat to the Strategic National Stockpile.

*Tecovirimat is an investigational product that is not currently commercially available in the United States. It has not been determined by the U.S. Food and Drug Administration to be safe and effective for the treatment of smallpox or any other indication.